Research

Two molecular signaling pathways underlie the cardiac defects associated with one type of the inherited disorder Noonan syndrome (NS), researchers from Masonic Medical Research Institute, Beth Israel Deaconess Medical Center and Weill Cornell Medicine find in a new study.

A newly available drug may improve the effectiveness of immunotherapy in hard-to-treat cancers of the upper urinary tract, suggests a study published by Weill Cornell Medicine and NewYork-Presbyterian investigators.

A new study published July 8 in the Annals of Internal Medicine demonstrates that pregnancy outcomes in the last two decades have drastically improved for patients with systemic lupus erythematosus.

A new technology devised by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC) enables the measurement of gene mutations and their effects on gene activity within individual cancer cells biopsied from patients.

Early disruptions in brain cell activity may give rise to autism.

Studying the Fundamentals of Bone Strength, Pathologist Dr.  Matthew Greenblatt Aims to Protect People from Osteoporosis

Responding to the growing prevalence of obesity in the United States, an alliance of professional medical societies has developed the first competencies for training and evaluating medical students, residents and fellows on preventing, assessing and treating the condition. The new competencies were published June 24 in the journal Obesity and highlighted as an Editor’s Choice article.

A physician-author sounds the alarm about drug-resistant bacteria—and shares his own experiences on the front lines of treatment.

Physicians, researchers and policymakers around the globe are grappling with the rise of antibiotic-resistant bacteria—a threat with the potential to derail decades of medical advances.

Two Weill Cornell Medicine physician-scientists, Dr. Anthony Rosen and Dr. Neel Naik, were recently recognized by the Society of Academic Emergency Medicine for their contributions to the field of emergency medicine.

One of the most successful interventions in reducing infectious disease worldwide, vaccination still has limited effectiveness in protecting one group of patients – newborn infants. 

Dr. Jonathan Shoag, a urologic oncology fellow and instructor of urology at Weill Cornell Medicine, has been named a winner of this year’s prestigious Damon Runyon Physician-Scientist Training Award.

Findings from a recent study by a team of Weill Cornell Medicine and NewYork-Presbyterian researchers explain why a bladder cancer patient responded exceptionally well to a targeted drug when others did not. 

The event, sponsored by the institution’s BioVenture eLab, is the culmination of a nine-week mentoring program that is designed to improve the ability of Weill Cornell Medicine clinicians and researchers to commercialize their concepts.

A new technique developed by Weill Cornell Medicine investigators that creates an unusually stable form of RNA may illuminate many cellular processes and enable new kinds of gene therapies.

Dr. Matthew Greenblatt, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine, has been awarded the 2019 Pershing Square Sohn Prize for Young Investigators in Cancer Research to support his work studying tumor growth in bone.    

While heart attacks that cause classic symptoms such as pressure and pain in the chest are an established risk factor for stroke because they can lead to blood clot formation, new research by Weill Cornell Medicine and NewYork-Presbyterian investigators indicates that heart attacks that have few, if any, recognized symptoms may also increase risk.

The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

The chemical element selenium, an essential nutrient for humans and other animals, protects the brain after a stroke and may be a basis for future stroke therapies, according to a study from scientists at Burke Neurological Institute and Weill Cornell Medicine.

A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers.